In the present study, we demonstrate that the MEK inhibitors Trametinib, Selumetinib and MEK162 display strong anti-leukemic effects against RAS-mutant MLL-rearranged ALL cells. Here, KMT2A is linked to acute lymphoblastic leukemia.